Analyst Reco. WELL Health Technologies Corp.

Equities

WELL

CA94947L1022

Delayed Toronto S.E. Other stock markets 01:27:35 2024-04-24 pm EDT			5-day change	1st Jan Change
3.585 ^CAD	-0.97%		+1.56%	-6.88%

Apr. 18	WELL Health Maintained at Buy at Stifel GMP as it Buys 10 Clinics From Shoppers Drug Mart; Price Target Kept at C$11.00	MT
Apr. 17	WELL Health Technologies Rises 3%, TD Says Shopper Drug Mart Deal Likely For "Low Price"	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

WELL Health Maintained at Buy at Stifel GMP as it Buys 10 Clinics From Shoppers Drug Mart; Price Target Kept at C$11.00	Apr. 18	MT
WELL Health Technologies Rises 3%, TD Says Shopper Drug Mart Deal Likely For "Low Price"	Apr. 17	MT
WELL Health Technologies Initiated at Outperform, $5.50 Price Target at RBC	Feb. 06	MT
Well Health Brief: Says Achieved record quarterly revenues of $204.5 million; Raises Guidance for Balance of 2023 and Provides Guidance of Over $900 Million in Revenue for 2024	Nov. 14	MT
WELL Health Technologies Maintained at Buy at Stifel GMP Following Clinic Acquisitions; Price Target Kept at C$13.50	23-05-23	MT
WELL Health Technologies Initiated at Outperform, $8.50 Price Target at Raymond James	23-04-25	MT
WELL Health Technologies Buy Rating Reiterated at Stifel GMP Following Good Q4 Results; Price Target Kept at C$13.50	23-03-22	MT
WELL Health Reports Record Revenue and Adjusted EBITDA Results for Q3-2022 and Raises Guidance for Fourth Straight Quarter	22-11-10	PR
WELL Health Technologies : Reports Record Revenue and Adjusted EBITDA Results for Q3-2022 and Raises Guidance for Fourth Straight Quarter	22-11-10	PU
WELL Health Reports Record Quarterly Revenue and Adjusted EBITDA in Q2-2022 and Raises Guidance for 3rd Straight Quarter	22-08-11	AQ
WELL Health Technologies Buy Rating Kept at Stifel GMP as Credit Facility Expanded	22-07-19	MT
WELL Health Technologies Kept at Buy at Stifel GMP Following Formation of a Canadian Clinic Unit	22-07-15	MT
Scotiabank's Take on Well Health's INLIV Acquisition	22-06-21	MT
Scotiabank Maintains Outperform, $9 TP on Well Health After Company Releases Prelim Q1 Results	22-04-26	MT
GUIDANCE: (WELL.TO) WELL HEALTH TECHNOLOGIES Adds This "Catapults" Its Estimated Proforma Annualized Revs Run Rate to Almost $400 Million with Adjusted EBITDA Run Rate Approaching $100 Million	21-08-12	MT
Well Health Brief: In initiating Coverage, Scotia Analyst Adam Buckham Set a TP of $10.00/share and a 25.2% Rate of Return on Shares Within Next 12 Months, While Opening with a Sector Perform Rating, Cantech has noted	21-07-20	MT
Well Health Brief: Scotiabank Has Sector Perform and $10 Price Target on It Vs Mostly Buy Ratings and Average PT on Bay Street of More Than $11.50, notes BNN TV	21-07-19	MT
WELL HEALTH TECHNOLOGIES : Target Price Increased to $11 at TD, Analyst Sees More Acquisitions	21-06-08	MT
WELL HEALTH TECHNOLOGIES : Rises More than 5%, TD Says MyHealth Acquisition Likely To Be Viewed "Positively"	21-06-07	MT
WELL HEALTH TECHNOLOGIES : Upgraded to Buy After Intrahealth Acquisition	21-03-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. WELL Health Technologies Corp.

Equities

WELL

CA94947L1022

Analyst Reco.

Filters